What is Definium Therapeutics accused of in the lawsuit?

Definium Therapeutics is accused of stealing trade secrets related to its LSD clinical trials and sharing confidential information with a rival company, EMA Wellness.

Who filed the lawsuit against Definium Therapeutics?

Signant Health, a clinical trial provider that previously worked with Definium, filed the lawsuit.

What does Signant Health seek in its lawsuit against Definium?

Signant Health is seeking unspecified monetary damages and a court order to prevent Definium from misusing its trade secrets.

Home / Business and Economy / Psychedelic Firm Sued for Trade Secret Theft

Psychedelic Firm Sued for Trade Secret Theft

3 Feb

•

Summary

Signant Health claims Definium stole trade secrets for LSD trials.
Definium allegedly shared confidential data with rival EMA Wellness.
Lawsuit seeks monetary damages and injunction against trade secret misuse.

Psychedelic Firm Sued for Trade Secret Theft

Signant Health filed a lawsuit on February 2, 2026, accusing Definium Therapeutics of stealing trade secrets. The legal action alleges that Definium improperly shared confidential information related to its clinical trials for an LSD therapy with a rival company, EMA Wellness.

Definium, formerly known as MindMed, is developing an LSD treatment for severe depression and anxiety. Signant Health assisted Definium with its Phase 2 trials starting in 2021. The lawsuit claims that Todd Solomon, an executive at Definium, holds a stake in EMA Wellness and secretly ensured EMA's selection for Phase 3 trials.

According to the lawsuit, Definium and Solomon aided EMA in replicating Signant's clinical trial platform by sharing proprietary data. Signant is seeking monetary damages and a court order to halt the misuse of its trade secrets.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.